First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

NCT02729298 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

177

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
EGFR Positive Non-small Cell Lung Cancer
Colorectal Carcinoma
Recurrent Ovarian Carcinoma
BRAF-Mutated Melanoma

Interventions

DRUG: TP-0903

Sponsor

Sumitomo Pharma America, Inc.